DRF-2519 is a dual PPARα/γ activator. It has better reduction of plasma insulin, triglyceride, and free fatty acid levels in treated cells compared to those treated with rosiglitazone.
1. Chakrabarti, R., et al. 2004. Eur. J. Pharmacol. 491: 195-206. PMID: 15140637
2. Madhavan, G.R., et al. 2006. Bioorg. Med. Chem. 14: 584-591. PMID: 16198573
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.